HDCN Abstract:  ASN Annual Meeting 2020 -- Digital Meeting  

Wong EK, Praga M, Nester CM, et al.

LNP023: A Novel Oral Complement Alternative Pathway Factor B Inhibitor Safely and Effectively Reduces Proteinuria in C3 Glomerulopathy

ASN Annual Meeting 2020 -- Digital Meeting
J Am Soc Nephrol (Oct) 31:55A 2020


LNP023 is a highly selective oral low molecular weight inhibitor of complement Factor B, a key alternative pathway (AP) protease. The aim of the preliminary interim analysis (IA) of this Phase 2 study (NCT03832114) was to determine whether LNP023 safely and effectively reduces proteinuria in patients with C3 glomerulopathy (C3G).


Adults with biopsy-proven native C3G received open-label LNP023 for 12w (10-100mg bid during w1-3 then 200mg bid w4-12). All had proteinuria >1g/24h, low plasma C3, stable ACEi/ARB and were vaccinated vs. encapsulated bacteria. Complement inhibition was measured by the ex vivo Wieslab assay and fragment Bb and soluble C5b- 9 (sC5b-9) levels. Study primary end-point was the ratio of UPCR at 12w vs. baseline. On study completion, all patients received ongoing LNP023 in a long -term extension study (NCT03955445).


7 patients completed therapy at the time of this IA: mean (range) age 25 (18-39)y, median (range) eGFR 80 (29-130)ml/min/1.73m2. There were no treatment discontinuations. UPCR levels fell by 53% (80% CI 40-64%) from a Geo-Mean (Geo-CV%) value of 399 (67.6)mg/mmol at baseline to 187 (104.3)mg/mmol at 12w, p=0.0035. eGFR improved or stabilised; median (IQR) change +4.0 ml/min/1.73m2 (-0.5 - +7.5ml/min/1.73m2). There were no deaths or treatment-emergent SAEs. Blood and urine complement biomarkers confirmed abnormal pre-dosing AP activity in all. Plasma C3 levels recovered, with complete normalisation in 5/7 at 12w. LNP023 inhibited AP activity, with maximal effects obtained at 100mg to 200mg bid (median percent changes from BL at maximum inhibition were Wieslab: -66.3% (N=5), plasma Bb: -13.6% (N=5), plasma SC5b-9 (N=6): -75.9%, urine SC5b-9: -94.9% (N=4)). There was little impact of reduced eGFR on LNP023 systemic exposure. In 6 patients who have entered the long-term extension study to date, there has been a further reduction in proteinuria; Geo-CV% UPCR value at 6m was 129 (109.9)mg/mmol, a fall of 67.7% from baseline.


LNP023 200mg bid resulted in AP blockade and reduced proteinuria in patients with C3G treated for 12w with excellent safety and tolerability. Extended treatment resulted in further proteinuria reduction.

c Copyright 2020 -2021 American Society of Nephrology. Reproduced with permission.
All ASN abstracts from the 2020 Annual Meeting are available at this link and also are archived in .pdf form at ASN-Online.org

Disclaimer: Abstracts often have errors, both typographical and otherwise. This posting is an electronic translation of submitted abstracts which has not been verified against the original submitted abstract nor with the authors for accuracy. As a result, there may be errors, especially with regard to drug doses, but not limited to these. Abstracts undergo only limited review, and data often are changed as a result of the peer review process, so their reliability is less than manuscripts published in peer-reviewed journals. In using these summaries, you are agreeing that you are aware of these limitations.

The materials are provided on an as-is basis without any warranty of any kind, either express or implied. In addition to errors, the information presented may be incomplete or outdated. The information contained is not intended nor recommended as a substitute for professional medical advice. You are advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each device to be used or drug to be administered to verify the dosage, the method and duration of administration, or contraindications. It is the responsibility of the treating physician or other health care professional, relying on independent experience and knowledge of the patient, to determine drug, disease, and the best treatment for the patient.

To the fullest extent permitted by law, HDCN, ASN and their affiliates and suppliers disclaim all warranties, express or implied, including, but not limited to, any warranty of merchantability, non- infringement or fitness for a particular purpose.

In no event shall HDCN, ASN, or their affiliates or suppliers be liable for any damages whatsoever (including, but not limited to, direct, indirect, incidental, consequential, punitive or exemplary damages, or any damages for loss of profits, use, data, goodwill or other intangibles) arising from or in any way relating to these terms, the materials, or any information, goods or services obtained from or referred to in the materials, whether based on warranty, contract, tort (including, but not limited to, negligence), or any other legal theory, and whether or not any or all of the limited entities is advised of the possibility of such damages.